Advertisement

Topics

Antibe Therapeutics Announces Enrollment of First Subjects in Phase 2B GI Safety Study for Lead ...

02:06 EDT 8 Sep 2017 | BioMedReports - Blog
Antibe Therapeutics Inc.
Dan Legault, 416-473-4095
Chief Executive Officer
dan.legault@antibethera.com

Read more...

Original Article: Antibe Therapeutics Announces Enrollment of First Subjects in Phase 2B GI Safety Study for Lead ...

NEXT ARTICLE

More From BioPortfolio on "Antibe Therapeutics Announces Enrollment of First Subjects in Phase 2B GI Safety Study for Lead ..."

Quick Search
Advertisement